ELISA, IA Optimal dilutions/concentrations should be determined by the end user.
General Notes
This antibody and can be used for the development of an analytical immunoassays for semaglutide. Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) analog used in the treatment of type 2 diabetes and obesity. Monitoring semaglutide levels is essential for ensuring therapeutic efficacy and avoiding side effects.
Citations
Publication ()
Have you cited CABT-L6359 in a publication? Let us know and earn a reward for your research.
Feasibility of a direct binding electrochemiluminescence assay to detect anti-drug antibodies against therapeutic peptides
Ruoxuan Sun, Janey Ronxhi, Xuemei Yang, Mark G Qian, Xiaobin Zhang
J Pharm Biomed Anal2025 Feb 15PubMed ID: 39615123Read Article
Applications: Immunoassay Reactive species: Unspecified reactive species
"Abstract: The emergence of anti-drug antibodies (ADAs) poses significant impacts on the bioactivity and toxicity of biotherapeutics including proteins and peptides. Developing reliable assays to monitor the magnitudes of ADAs in blood samples is therefore considered a crucial task in animal and human studies throughout the development of biotherapeutics. Peptides represent a significant and fast-growing category of biotherapeutics for the management of a variety of indications. While peptides generally exhibit lower immunogenicity risks compared to biologics of larger sizes, drug developers are still required to conduct the risk-based immunogenicity assessment as mandated by the regulatory authorities. To address the need for efficient detection of ADAs against therapeutic peptides, we established a straightforward electrochemiluminescence immunoassay (ECLIA) based on direct binding strategy. Our assay demonstrates its applicability across various peptide therapeutics including marketed drugs and internal investigational compounds. Through stepwise tuning of the assay procedure, we identified several key factors such as buffer, detection reagent, plate type, and conjugation strategy that collectively contribute to the assay performance. Depending on the drug molecule and positive control antibody, the assay can achieve low single-digit to two-digit ng/ml sensitivity and ideal drug tolerance. In conclusion, this ECLIA platform presents a valuable and generic tool to expedite the development and validation of ADA assays for peptide-based therapeutics." Article snippet: Anti-semaglutide rabbit polyclonal antibody was provided by Creative Diagnostics (Shirley, NY, USA).
Figure 1. Comparison of different assay formats for anti-semaglutide ADA assay in human and monkey plasma
My Review for Rabbit Anti-Semaglutide polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
